{"id":"g-bq-l14","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BTK is a key component of the B cell receptor signaling complex and plays a crucial role in the activation of B cells. Inhibiting BTK has been shown to be effective in treating various B cell malignancies. BQ-L14 has been designed to selectively target BTK, leading to the inhibition of B cell activation and proliferation.","oneSentence":"BQ-L14 is a small molecule that acts as a selective and potent inhibitor of the Bruton's tyrosine kinase (BTK).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:24:42.658Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory mantle cell lymphoma"},{"name":"Relapsed or refractory marginal zone lymphoma"}]},"trialDetails":[{"nctId":"NCT04713670","phase":"PHASE4","title":"Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-03-10","conditions":"H. Pylori Infection","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"(G) BQ-L14","genericName":"(G) BQ-L14","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BQ-L14 is a small molecule that acts as a selective and potent inhibitor of the Bruton's tyrosine kinase (BTK). Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}